These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22627607)

  • 1. Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy.
    Domingo P; Estrada V; López-Aldeguer J; Villaroya F; Martínez E
    AIDS Rev; 2012; 14(2):112-23. PubMed ID: 22627607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipodystrophy syndrome. Therapeutic progress is still pending].
    Weber K; Heiken H; Stoll M; Schmidt RE; Behrens G
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():28-32. PubMed ID: 15011581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term complications of antiretroviral therapy: lipoatrophy.
    Waters L; Nelson M
    Int J Clin Pract; 2007 Jun; 61(6):999-1014. PubMed ID: 17504362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral lipomastia in men: a side effect of highly active antiretroviral therapy.
    Deonarain J; Ramdial PK; Singh B
    Int J Surg Pathol; 2008 Apr; 16(2):171-5. PubMed ID: 18417674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
    Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevention and therapy of HIV-associated lipodystrophy syndrome and antiretroviral caused metabolic changes].
    Mauss S
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():49-53. PubMed ID: 16385875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HIV infection: emerging issues and new challenges].
    Calza L; Manfredi R; Chiodo F
    Recenti Prog Med; 2006 Dec; 97(12):771-80. PubMed ID: 17252736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
    Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
    Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives on HIV-associated lipodystrophy syndrome.
    Milinkovic A; Martinez E
    J Antimicrob Chemother; 2005 Jul; 56(1):6-9. PubMed ID: 15905302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
    Phillips DR; Hay P
    J Antimicrob Chemother; 2008 Nov; 62(5):866-71. PubMed ID: 18703527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body-fat abnormalities in patients with HIV: progress and challenges.
    Bedimo RJ
    J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):292-305. PubMed ID: 19056708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
    Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
    Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disorders of body fat distribution in HIV-1-infected patients.
    Moreno S; Miralles C; Negredo E; Domingo P; Estrada V; Gutiérrez F; Lozano F; Martínez E
    AIDS Rev; 2009; 11(3):126-34. PubMed ID: 19654854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S; Palmisano L
    J HIV Ther; 2003 May; 8(2):27-8. PubMed ID: 15587479
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.